Evaluating Chagas disease progression and cure through blood-derived biomarkers: a systematic review

References

• WHO. (Chagas Disease) American Tripanosomiasis. Fact Sheet. Nº 340. World Health Organization, (2010).
   Google Scholar
• WHO. Reporte Sobre La Enfermedad De CHAGAS. World Health Organization, Bueno Aires, (2007).
   Google Scholar
• WHO. Control and prevention of Chagas disease in Europe. Report of a WHO Informal Consultation (Jointly Organized By WHO Headquarters and The WHO Regional Office for Europe) Geneva, Switzerland, WHO/HTM/NTD/IDM/2010.1. World Health Organizatoin, Geneva, (2010).
   Google Scholar
• Rassi A Jr, Rassi A, Marin-Neto JA. Chagas disease. Lancet 375(9723), 1388–1402 (2010).
   PubMed Web of Science ®Google Scholar
• Rassi A Jr, Rassi A, Rassi SG. Predictors of mortality in chronic Chagas disease: a systematic review of observational studies. Circulation 115(9), 1101–1108 (2007).
   PubMed Web of Science ®Google Scholar
• Dias JC. The indeterminate form of human chronic Chagas’ disease A clinical epidemiological review. Rev. Soc. Bras. Med. Trop. 22(3), 147–156 (1989).
   PubMedGoogle Scholar
• Ribeiro ALP, Rocha MOdC. Indeterminate form of Chagas’ disease: considerations on diagnosis and prognosis. Rev. Soc. Bras. Med. Trop. 31(3), 301–314 (1998).
   PubMedGoogle Scholar
• Garcia-Alvarez A, Sitges M, Pinazo MJ et al. Chagas cardiomyopathy: the potential of diastolic dysfunction and brain natriuretic peptide in the early identification of cardiac damage. PLoS Negl. Trop. Dis. 4(9) (2010).
   PubMed Web of Science ®Google Scholar
• Cassarotti DJ, Giuseppin FF, Toledo MJdO, Gomes ML, Araujo SMd. Alterations in ecoDopplercadiogram in Chagas’ disease patients with normal ECG: preliminary data. Rev. Soc. Bras. Med. Trop. 41(Suppl. III), 194–196 (2008).
   Google Scholar
• Luengas CA, Chaves AM, Villamizar MC. Color M flow velocity propagation is a sensible diastolic dysfunction marker in Chagas cardiomyopathy. [Spanish]. Rev. Colombiana Cardiol. 15(6), 282–288 (2008).
   Google Scholar
• Perez-Ayala A, Perez-Molina JA, Norman F, Monge-Maillo B, Faro MV, Lopez-Velez R. Gastro-intestinal Chagas disease in migrants to Spain: prevalence and methods for early diagnosis. Ann. Trop. Med. Parasitol. 105(1), 25–29 (2011).
   PubMed Web of Science ®Google Scholar
• Andrade ZA. The indeterminate form of Chagas disease in times of Triatoma infestans control. Rev. Patol. Trop. 34(2), 105–111 (2005).
   Google Scholar
• Carrasco HA, Alarcon M, Olmos L et al. Biochemical characterization of myocardial damage in chronic Chagas’ disease. Clin. Cardiol. 20(10), 865–869 (1997).
   PubMedGoogle Scholar
• Bestetti RB, Freitas OC, Muccillo G, Oliveira JS. Clinical and morphological characteristics associated with sudden cardiac death in patients with Chagas’ disease. Eur. Heart J. 14(12), 1610–1614 (1993).
   PubMedGoogle Scholar
• Cianciulli TF, Lax JA, Saccheri MC et al. Early detection of left ventricular diastolic dysfunction in Chagas’ disease. Cardiovasc. Ultrasound 4, 18 (2006).
   Google Scholar
• Pazin-Filho A, Romano MM, Gomes Furtado R et al. Left ventricular global performance and diastolic function in indeterminate and cardiac forms of Chagas’ disease. J. Am. Soc. Echocardiogr. 20(12), 1338–1343 (2007).
   PubMedGoogle Scholar
• Murcia L, Carrilero B, Munoz MJ, Iborra MA, Segovia M. Usefulness of PCR for monitoring benznidazole response in patients with chronic Chagas’ disease: a prospective study in a non-disease-endemic country. J. Antimicrob. Chemother. 65(8), 1759–1764 (2010).
   PubMed Web of Science ®Google Scholar
• Gutierrez FR, Guedes PM, Gazzinelli RT, Silva JS. The role of parasite persistence in pathogenesis of Chagas heart disease. Parasite Immunol. 31(11), 673–685 (2009).
   PubMed Web of Science ®Google Scholar
• Higuchi Mde L, Benvenuti LA, Martins Reis M, Metzger M. Pathophysiology of the heart in Chagas’ disease: current status and new developments. Cardiovasc. Res. 60(1), 96–107 (2003).
   PubMedGoogle Scholar
• Dutra WO, Rocha MO, Teixeira MM. The clinical immunology of human Chagas disease. Trends Parasito. 21(12), 581–587 (2005).
   PubMedGoogle Scholar
• Zacks MA, Wen JJ, Vyatkina G, Bhatia V, Garg N. An overview of chagasic cardiomyopathy: pathogenic importance of oxidative stress. An. Acad. Bras. Cienc. 77(4), 695–715 (2005).
   PubMedGoogle Scholar
• Munoz-Saravia SG, Haberland A, Wallukat G, Schimke I. Chronic Chagas’ heart disease: a disease on its way to becoming a worldwide health problem: epidemiology, etiopathology, treatment, pathogenesis and laboratory medicine. Heart Fail. Rev. 17(1), 45–64 (2012).
   PubMedGoogle Scholar
• Cunha-Neto E, Nogueira LG, Teixeira PC et al. Immunological and non-immunological effects of cytokines and chemokines in the pathogenesis of chronic Chagas disease cardiomyopathy. Mem. Inst. Oswaldo. Cruz. 104(Suppl. 1), 252–258 (2009).
   PubMedGoogle Scholar
• Cunha-Neto E, Bilate AM, Hyland KV, Fonseca SG, Kalil J, Engman DM. Induction of cardiac autoimmunity in Chagas heart disease: a case for molecular mimicry. Autoimmunity 39(1), 41–54 (2006).
   PubMed Web of Science ®Google Scholar
• Bustamante JM, Bixby LM, Tarleton RL. Drug-induced cure drives conversion to a stable and protective CD8+ T central memory response in chronic Chagas disease. Nat. Med. 14(5), 542–550 (2008).
   PubMed Web of Science ®Google Scholar
• Vitelli-Avelar DM, Sathler-Avelar R, Teixeira-Carvalho A et al. Strategy to assess the overall cytokine profile of circulating leukocytes and its association with distinct clinical forms of human Chagas disease. Scand. J. Immunol. 68(5), 516–525 (2008).
   PubMed Web of Science ®Google Scholar
• Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N. Engl. J. Med. 323(4), 236–241 (1990).
   PubMed Web of Science ®Google Scholar
• Torre-Amione G, Kapadia S, Lee J et al. Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. Circulation 93(4), 704–711 (1996).
   PubMed Web of Science ®Google Scholar
• Feldman AM, Combes A, Wagner D et al. The role of tumor necrosis factor in the pathophysiology of heart failure. J. Am. Coll. Cardiol. 35(3), 537–544 (2000).
   PubMed Web of Science ®Google Scholar
• Talvani A, Rocha MO, Barcelos LS, Gomes YM, Ribeiro AL, Teixeira MM. Elevated concentrations of CCL2 and tumor necrosis factor-alpha in chagasic cardiomyopathy. Clin. Infect. Dis. 38(7), 943–950 (2004).
   PubMedGoogle Scholar
• Ferreira RC, Ianni BM, Abel LC et al. Increased plasma levels of tumor necrosis factor-alpha in asymptomatic/“indeterminate” and Chagas disease cardiomyopathy patients. Mem. Inst. Oswaldo. Cruz. 98(3), 407–411 (2003).
   PubMedGoogle Scholar
• Lula JF, Rocha MO, Nunes Mdo C et al. Plasma concentrations of tumour necrosis factor-alpha, tumour necrosis factor-related apoptosis-inducing ligand, and FasLigand/CD95L in patients with Chagas cardiomyopathy correlate with left ventricular dysfunction. Eur. J. Heart Fail. 11(9), 825–831 (2009).
   PubMedGoogle Scholar
• Moretti E, Basso B, Cervetta L, Brigada A, Barbieri G. Patterns of cytokines and soluble cellular receptors in the sera of children with acute Chagas’ disease. Clin. Diagn. Lab. Immunol. 9(6), 1324–1327 (2002).
   PubMedGoogle Scholar
• Gomes JA, Bahia-Oliveira LM, Rocha MO, Martins-Filho OA, Gazzinelli G, Correa-Oliveira R. Evidence that development of severe cardiomyopathy in human Chagas’ disease is due to a Th1-specific immune response. Infect. Immun. 71(3), 1185–1193 (2003).
   PubMed Web of Science ®Google Scholar
• Laucella SA, Mazliah DP, Bertocchi G et al. Changes in Trypanosoma cruzi-specific immune responses after treatment: surrogate markers of treatment efficacy. Clin. Infect. Dis. 49(11), 1675–1684 (2009).
   PubMed Web of Science ®Google Scholar
• Hunt SA, Abraham WT, Chin MH et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 119(14), e391–479 (2009).
   PubMedGoogle Scholar
• Wang Y, Moreira Mda C, Heringer-Walther S et al. Amino-terminal fragment of C-type natriuretic peptide precursor and C-type natriuretic peptide do not correlate in patients with Chagas disease: role for neutral endopeptidase. J. Cardiovasc. Pharmacol. 55(1), 62–66 (2010).
   PubMedGoogle Scholar
• Ribeiro AL, dos Reis AM, Barros MV et al. Brain natriuretic peptide and left ventricular dysfunction in Chagas’ disease. Lancet, 360(9331), 461–462 (2002).
   PubMed Web of Science ®Google Scholar
• Talvani A, Rocha MO, Cogan J et al. Brain natriuretic peptide and left ventricular dysfunction in chagasic cardiomyopathy. Mem. Inst. Oswaldo. Cruz. 99(6), 645–649 (2004).
   PubMed Web of Science ®Google Scholar
• Barbosa MM, Nunes Mdo C, Ribeiro AL, Barral MM, Rocha MO. N-terminal proBNP levels in patients with Chagas disease: a marker of systolic and diastolic dysfunction of the left ventricle. Eur. J. Echocardiogr. 8(3), 204–212 (2007).
   PubMed Web of Science ®Google Scholar
• Heringer-Walther S, Moreira MC, Wessel N et al. Brain natriuretic peptide predicts survival in Chagas’ disease more effectively than atrial natriuretic peptide. Heart 91(3), 385–387 (2005).
   PubMed Web of Science ®Google Scholar
• Melo RB, Parente GB, Victor EG. [Measurement of human brain natriuretic peptide in patients with Chagas’ disease]. Arq. Bras. Cardiol. 84(2), 137–140 (2005).
   PubMedGoogle Scholar
• Mady C, Fernandes F, Arteaga E et al. Serum NT pro-BNP: relation to systolic and diastolic function in cardiomyopathies and pericardiopathies. Arq. Bras. Cardiol. 91(1), 46–54 (2008).
   PubMed Web of Science ®Google Scholar
• Talvani A, Rocha MO, Cogan J et al. Brain natriuretic peptide measurement in Chagas heart disease: marker of ventricular dysfunction and arrhythmia. Int. J. Cardiol. 100(3), 503–504 (2005).
   PubMedGoogle Scholar
• Ribeiro AL, Teixeira MM, Reis AM et al. Brain natriuretic peptide based strategy to detect left ventricular dysfunction in Chagas disease: a comparison with the conventional approach. Int. J. Cardiol. 109(1), 34–40 (2006).
   PubMedGoogle Scholar
• Moreira Mda C, Heringer-Walther S, Wessel N et al. Prognostic value of natriuretic peptides in Chagas’ disease: a 3-year follow-up investigation. Cardiology 110(4), 217–225 (2008).
   PubMed Web of Science ®Google Scholar
• Lima-Costa MF, Cesar CC, Peixoto SV, Ribeiro AL. Plasma B-type natriuretic peptide as a predictor of mortality in community-dwelling older adults with Chagas disease: 10-year follow-up of the Bambui Cohort Study of Aging. Am. J. Epidemiol. 172(2), 190–196 (2010).
   PubMed Web of Science ®Google Scholar
• Moreira Mda C, Wang Y, Heringer-Walther S, Wessel N, Walther T. Prognostic value of natriuretic peptides in Chagas’ disease: a head-to-head comparison of the 3 natriuretic peptides. Congest. Heart Fail. 15(2), 75–81 (2009).
   PubMedGoogle Scholar
• Puyo AM, Scaglione J, Auger S et al. Atrial natriuretic factor as marker of myocardial compromise in Chagas’ disease. Regul. Pept. 105(2), 139–143 (2002).
   PubMedGoogle Scholar
• Puyo AM, Scaglione J, Auger S, Cavallero S, Postan M, Fernandez BE. Natriuretic peptides as prognostic and diagnostic markers in Chagas’ disease. Regul. Pept. 128(3), 203–210 (2005).
   PubMedGoogle Scholar
• Mocelin AO, Issa VS, Bacal F, Guimaraes GV, Cunha E, Bocchi EA. The influence of aetiology on inflammatory and neurohumoral activation in patients with severe heart failure: a prospective study comparing Chagas’ heart disease and idiopathic dilated cardiomyopathy. Eur. J. Heart Fail. 7(5), 869–873 (2005).
   PubMedGoogle Scholar
• La Vecchia L, Mezzena G, Zanolla L et al. Cardiac troponin I as diagnostic and prognostic marker in severe heart failure. J. Heart Lung. Transplant. 19(7), 644–652 (2000).
   PubMed Web of Science ®Google Scholar
• Saravia SG, Knebel F, Schroeckh S et al. Cardiac troponin T release and inflammation demonstrated in marathon runners. Clin. Lab. 56(1–2), 51–58 (2010).
   PubMed Web of Science ®Google Scholar
• Arias R, Bastos C, Mota G et al. Troponin in Chagas disease. Braz. J. Infect. Dis. 7(6), 358–359 (2003).
   PubMedGoogle Scholar
• Saravia SG, Haberland A, Bartel S et al. Cardiac troponin T measured with a highly sensitive assay for diagnosis and monitoring of heart injury in chronic Chagas disease. Arch. Pathol. Lab. Med. 135(2), 243–248 (2011).
   PubMedGoogle Scholar
• Basquiera AL, Capra R, Omelianiuk M, Amuchastegui M, Madoery RJ, Salomone OA. [Serum troponin T in patients with chronic Chagas disease]. Rev. Esp. Cardiol. 56(7), 742–744 (2003).
   PubMedGoogle Scholar
• Epelman S, Tang WH, Chen SY, Van Lente F, Francis GS, Sen S. Detection of soluble angiotensin-converting enzyme 2 in heart failure: insights into the endogenous counter-regulatory pathway of the renin-angiotensin-aldosterone system. J Am Coll Cardiol, 52(9), 750–754 (2008).
   PubMed Web of Science ®Google Scholar
• Wang Y, Moreira Mda C, Heringer-Walther S et al. Plasma ACE2 activity is an independent prognostic marker in Chagas’ disease and equally potent as BNP. J. Card. Fail. 16(2), 157–163 (2010).
   PubMed Web of Science ®Google Scholar
• de Oliveira TB, Pedrosa RC, Filho DW. Oxidative stress in chronic cardiopathy associated with Chagas disease. Int. J. Cardiol. 116(3), 357–363 (2007).
   PubMed Web of Science ®Google Scholar
• Gupta S, Wen JJ, Garg NJ. Oxidative Stress in Chagas Disease. Interdiscip. Perspect. Infect. Dis. 2009, 190354 (2009).
   PubMedGoogle Scholar
• Macao LB, Wilhelm Filho D, Pedrosa RC et al. Antioxidant therapy attenuates oxidative stress in chronic cardiopathy associated with Chagas’ disease. Int. J. Cardiol. 123(1), 43–49 (2007).
   PubMedGoogle Scholar
• Cardenas ME, Torres D, Mujica AM, Sanabria JS. The L-Arginine-Nitric oxide-Peroxynitrite pathway (LANOP pathway): does it protect or worsen the course of Chagas disease? Colombia Medica 41(4), 388–395 (2010).
   Google Scholar
• Perez-Fuentes R, Torres-Rasgado E, Salgado-Rosas H, Zamora-Ginez I, Sanchez-Guillen MC. The anti-oxidant defence response in individuals with the indeterminate form of Chagas disease (American trypanosomiasis). Ann. Trop. Med. Parasitol. 102(3), 189–197 (2008).
   PubMed Web of Science ®Google Scholar
• Perez-Fuentes R, Guegan JF, Barnabe C et al. Severity of chronic Chagas disease is associated with cytokine/antioxidant imbalance in chronically infected individuals. Int. J. Parasitol. 33(3), 293–299 (2003).
   PubMed Web of Science ®Google Scholar
• Dhiman M, Estrada-Franco JG, Pando JM et al. Increased myeloperoxidase activity and protein nitration are indicators of inflammation in patients with Chagas’ disease. Clin. Vaccine Immunol. 16(5), 660–666 (2009).
   PubMed Web of Science ®Google Scholar
• Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J. Clin. Invest. 111(12), 1805–1812 (2003).
   PubMed Web of Science ®Google Scholar
• Aparecida da Silva C, Fattori A, Sousa AL et al. Determining the C-reactive protein level in patients with different clinical forms of chagas disease. Rev. Esp. Cardiol. 63(9), 1096–1099 (2010).
   PubMedGoogle Scholar
• Lopez L, Arai K, Gimenez E et al. [C-reactive protein and interleukin-6 serum levels increase as Chagas disease progresses towards cardiac failure]. Rev. Esp. Cardiol. 59(1), 50–56 (2006).
   PubMedGoogle Scholar
• Garcia-Alvarez A, Sitges M, Heras M et al. [Endothelial function and high-sensitivity C-reactive protein levels in patients with Chagas disease living in a nonendemic area]. Rev. Esp. Cardiol. 64(10), 891–896 (2011).
   PubMedGoogle Scholar
• Cunha-Neto E, Kalil J. Autoimmunity in Chagas’ heart disease. Sao. Paulo. Med. J. 113(2), 757–766 (1995).
   PubMedGoogle Scholar
• Kierszenbaum F. Where do we stand on the autoimmunity hypothesis of Chagas disease? Trends. Parasitol. 21(11), 513–516 (2005).
   PubMed Web of Science ®Google Scholar
• Cossio PM, Laguens RP, Diez C, Szarfman A, Segal A, Arana RM. Chagasic cardiopathy. Antibodies reacting with plasma membrane of striated muscle and endothelial cells. Circulation 50(6), 1252–1259 (1974).
   PubMedGoogle Scholar
• Cossio PM, Diez C, Szarfman A, Kreutzer E, Candiolo B, Arana RM. Chagasic cardiopathy. Demonstration of a serum gamma globulin factor which reacts with endocardium and vascular structures. Circulation 49(1), 13–21 (1974).
   PubMedGoogle Scholar
• Khoury EL, Diez C, Cossio PM, Arana RM. Heterophil nature of EVI antibody in Trypanosoma cruzi infection. Clin. Immunol. Immunopathol. 27(2), 283–288 (1983).
   PubMedGoogle Scholar
• Santos-Buch CA, Acosta AM, Zweerink HJ et al. Primary muscle disease: definition of a 25-kDa polypeptide myopathic specific chagas antigen. Clin. Immunol. Immunopathol. 37(3), 334–350 (1985).
   PubMedGoogle Scholar
• Rose NR, Hill SL. Autoimmune myocarditis. Int. J. Cardiol. 54(2), 171–175 (1996).
   PubMedGoogle Scholar
• Cunningham MW. Autoimmunity and molecular mimicry in the pathogenesis of post-streptococcal heart disease. Front. Biosci. 8, s533–543 (2003).
   Web of Science ®Google Scholar
• Rizzo LV, Cunha-Neto E, Teixeira AR. Autoimmunity in Chagas’ disease: specific inhibition of reactivity of CD4+ T cells against myosin in mice chronically infected with Trypanosoma cruzi. Infect. Immun. 57(9), 2640–2644 (1989).
   PubMedGoogle Scholar
• Leon JS, Wang K, Engman DM. Myosin autoimmunity is not essential for cardiac inflammation in acute Chagas’ disease. J Immunol, 171(8), 4271–4277 (2003).
   PubMedGoogle Scholar
• Tibbetts RS, McCormick TS, Rowland EC, Miller SD, Engman DM. Cardiac antigen-specific autoantibody production is associated with cardiomyopathy in Trypanosoma cruzi-infected mice. J. Immunol. 152(3), 1493–1499 (1994).
   PubMedGoogle Scholar
• Iwai LK, Juliano MA, Juliano L, Kalil J, Cunha-Neto E. T-cell molecular mimicry in Chagas disease: identification and partial structural analysis of multiple cross-reactive epitopes between Trypanosoma cruzi B13 and cardiac myosin heavy chain. J. Autoimmun. 24(2), 111–117 (2005).
   PubMedGoogle Scholar
• Cunha-Neto E, Duranti M, Gruber A et al. Autoimmunity in Chagas disease cardiopathy: biological relevance of a cardiac myosin-specific epitope crossreactive to an immunodominant Trypanosoma. cruzi antigen. Proc. Natl. Acad. Sci. USA. 92(8), 3541–3545 (1995).
   PubMedGoogle Scholar
• Laguens RP, Argel MI, Chambo J, Storino R, Cabeza Meckert PM. Presence of antiheart and antiskeletal muscle glycolipid autoantibodies in the sera of patients with chagasic cardiopathy. Can. J. Cardiol. 10(7), 769–776 (1994).
   PubMedGoogle Scholar
• de Oliveira SF, Pedrosa RC, Nascimento JH, Campos de Carvalho AC, Masuda MO. Sera from chronic chagasic patients with complex cardiac arrhythmias depress electrogenesis and conduction in isolated rabbit hearts. Circulation 96(6), 2031–2037 (1997).
   PubMedGoogle Scholar
• Arce-Fonseca M, Ballinas-Verdugo MA, Reyes PA, Aranda-Fraustro A, Monteon VM. Autoantibodies to human heart conduction system in Chagas’ disease. Vector Borne Zoonotic Dis. 5(3), 233–236 (2005).
   PubMedGoogle Scholar
• Wallukat G, Nissen E, Morwinski R, Muller J. Autoantibodies against the beta- and muscarinic receptors in cardiomyopathy. Herz 25(3), 261–266 (2000).
   PubMedGoogle Scholar
• Wallukat G, Saravia SGM, Haberland A et al. Distinct patterns of autoantibodies against G-protein-coupled receptors in Chagas’ cardiomyopathy and megacolon: their potential impact for early risk assessment in asymptomatic Chagas’ patients. J. Am. Coll. Cardiol. 55(5), 463–468 (2010).
   PubMedGoogle Scholar
• Munoz Saravia SG, Haberland A, Bartel S et al. Distinct patterns of autoantibodies against G-protein-coupled receptors in Chagas’ cardiomyopathy and megacolon: their potential impact for early risk assessment in asymptomatic Chagas’ patients. J. Am. Coll. Cardiol. 56(6), 526–527 (2010).
   PubMedGoogle Scholar
• Borda ES, Sterin-Borda L. Antiadrenergic and muscarinic receptor antibodies in Chagas’ cardiomyopathy. Int. J. Cardiol. 54(2), 149–156 (1996).
   PubMedGoogle Scholar
• Ribeiro AL, Gimenez LE, Hernandez CC et al. Early occurrence of anti-muscarinic autoantibodies and abnormal vagal modulation in Chagas disease. Int. J. Cardiol. 117(1), 59–63 (2007).
   PubMedGoogle Scholar
• Sterin-Borda L, Borda E. Role of neurotransmitter autoantibodies in the pathogenesis of chagasic peripheral dysautonomia. Ann. NY. Acad. Sci. 917, 273–280 (2000).
   PubMed Web of Science ®Google Scholar
• Giordanengo L, Gea S, Barbieri G, Rabinovich GA. Anti-galectin-1 autoantibodies in human Trypanosoma cruzi infection: differential expression of this beta-galactoside-binding protein in cardiac Chagas’ disease. Clin. Exp. Immunol. 124(2), 266–273 (2001).
   PubMedGoogle Scholar
• Girones N, Rodriguez CI, Basso B et al. Antibodies to an epitope from the Cha human autoantigen are markers of Chagas’ disease. Clin. Diagn. Lab. Immunol. 8(6), 1039–1043 (2001).
   PubMedGoogle Scholar
• da Silveira AB, D’Avila Reis D, de Oliveira EC et al. Neurochemical coding of the enteric nervous system in chagasic patients with megacolon. Dig. Dis. Sci. 52(10), 2877–2883 (2007).
   PubMedGoogle Scholar
• Adad SJ, Cançado CG, Etchebehere RM et al. Neuron count reevaluation in the myenteric plexus of chagasic megacolon after morphometric neuron analysis. Virchows Arch. 438(3), 254–258 (2001).
   PubMedGoogle Scholar
• da Silveira AB, Lemos EM, Adad SJ, Correa-Oliveira R, Furness JB, D’Avila Reis D. Megacolon in Chagas disease: a study of inflammatory cells, enteric nerves, and glial cells. Hum. Pathol. 38(8), 1256–1264 (2007).
   PubMedGoogle Scholar
• Iantorno G, Bassotti G, Kogan Z et al. The enteric nervous system in chagasic and idiopathic megacolon. Am. J. Surg. Pathol. 31(3), 460–468 (2007).
   PubMedGoogle Scholar
• Silveira ABMd, Freitas MAR, Oliveira ECd, et al. Neuronal plasticity of the enteric nervous system is correlated with chagasic megacolon development. Parasitology 135(11), 1337–1342 (2008).
   PubMedGoogle Scholar
• Cooley G, Etheridge RD, Boehlke C et al. High throughput selection of effective serodiagnostics for Trypanosoma cruzi infection. PLoS Negl. Trop. Dis 2(10), e316 (2008).
   PubMed Web of Science ®Google Scholar
• da Silveira JF, Umezawa ES, Luquetti AO. Chagas disease: recombinant Trypanosoma cruzi antigens for serological diagnosis. Trends Parasitol. 17(6), 286–291 (2001).
   PubMed Web of Science ®Google Scholar
• Betonico GN, Miranda EO, Silva DAO et al. Evaluation of a synthetic tripeptide as antigen for detection of IgM and IgG antibodies to Trypanosoma cruzi in serum samples from patients with Chagas disease or viral diseases. Trans. R. Soc. Trop. Med. Hyg. 93(6), 603–606 (1999).
   PubMedGoogle Scholar
• Chang CD, Cheng KY, Jiang LX et al. Evaluation of a prototype Trypanosoma cruzi antibody assay with recombinant antigens on a fully automated chemiluminescence analyzer for blood donor screening. Transfusion 46(10), 1737–1744 (2006).
   PubMedGoogle Scholar
• Sasaki AT, Hoshino-Shimizu S, Nakamura PM, Vaz AJ, Camargo ED, da Silva MV. Serodiagnosis of Chagas disease: new reagent for the indirect hemagglutination test (THAI(IAL)). [Portuguese]. Rev. Soc. Bras. Med. Trop. 29(2), 137–144 (1996).
   PubMedGoogle Scholar
• Caballero ZC, Sousa OE, Marques WP, Saez-Alquezar A, Umezawa ES. Evaluation of serological tests to identify Trypanosoma cruzi infection in humans and determine cross-reactivity with Trypanosoma rangeli and Leishmania spp. Clin. Vaccine Immunol. 14(8), 1045–1049 (2007).
   PubMed Web of Science ®Google Scholar
• Cançado JR. Long term evaluation of etiological treatment of chagas disease with benznidazole. Rev. Inst. Med. Trop. Sao. Paulo. 44(1), 29–37 (2002).
   PubMedGoogle Scholar
• Cançado JR. Criteria of Chagas disease cure. Mem. Inst. Oswaldo Cruz 94(Suppl. 1), 331–335 (1999).
   PubMedGoogle Scholar
• Viotti R, Vigliano C, Alvarez MG et al. Impact of aetiological treatment on conventional and multiplex serology in chronic chagas disease. PLoS Negl. Trop. Dis. 5(9), e1314 (2011).
   PubMed Web of Science ®Google Scholar
• Sabino EC, Lee TH, Montalvo L et al. Antibody levels correlate with detection of Trypanosoma cruzi DNA by sensitive polymerase chain reaction assays in seropositive blood donors and possible resolution of infection over time. Transfusion 53(6), 1257–1265 (2013).
   PubMedGoogle Scholar
• Zulantay I, Venegas J, Apt W, Solari A, Sanchez G. Lytic antibodies in Trypanosoma cruzi-infected persons with low parasitemia. Am. J. Trop. Med. Hyg. 58(6), 775–779 (1998).
   PubMedGoogle Scholar
• Krettli AU. The utility of anti-trypomastigote lytic antibodies for determining cure of Trypanosoma cruzi infections in treated patients: an overview and perspectives. Mem. Inst. Oswaldo Cruz 104(Suppl. 1), 142–151 (2009).
   PubMedGoogle Scholar
• Galvao LM, Nunes RM, Cançado JR, Brener Z, Krettli AU. Lytic antibody titre as a means of assessing cure after treatment of Chagas disease: a 10 years follow-up study. Trans. R. Soc. Trop. Med. Hyg. 87(2), 220–223 (1993).
   PubMed Web of Science ®Google Scholar
• Meira WS, Galvao LM, Gontijo ED, Machado-Coelho GL, Norris KA, Chiari E. Use of the Trypanosoma cruzi recombinant complement regulatory protein to evaluate therapeutic efficacy following treatment of chronic chagasic patients. J. Clin. Microbiol. 42(2), 707–712 (2004).
   PubMed Web of Science ®Google Scholar
• Levy AM, Boainain E, Kloetzel JK. In situ indirect fluorescent antibody: a new specific test to detect ongoing chagasic infections. J. Clin. Lab. Anal. 10(2), 98–103 (1996).
   PubMed Web of Science ®Google Scholar
• Altcheh J, Corral R, Biancardi MA, Freilij H. [Anti-F2/3 antibodies as cure marker in children with congenital Trypanosoma cruzi infection]. Medicina (B Aires), 63(1), 37–40 (2003).
   PubMed Web of Science ®Google Scholar
• Andrade AL, Martelli CM, Oliveira RM et al. Short report: benznidazole efficacy among Trypanosoma cruzi-infected adolescents after a six-year follow-up. Am. J. Trop. Med. Hyg. 71(5), 594–597 (2004).
   PubMed Web of Science ®Google Scholar
• Laucella SA, Titto EHd, Segura EL. Epitopes common to Trypanosoma cruzi and mammalian tissues are recognized by sera from Chagas’ disease patients: prognosis value in Chagas disease. Acta. Tropica. 62(3), 151–162 (1996).
   PubMedGoogle Scholar
• Fernandez-Villegas A, Pinazo MJ, Maranon C et al. Short-term follow-up of chagasic patients after benznidazole treatment using multiple serological markers. BMC Infect. Dis. 11, 206 (2011).
   PubMed Web of Science ®Google Scholar
• Flechas ID, Cuellar A, Cucunuba ZM et al. Characterising the KMP-11 and HSP-70 recombinant antigens’ humoral immune response profile in chagasic patients. BMC Infect. Dis. 9, 186 (2009).
   PubMedGoogle Scholar
• Fabbro DL, Olivera V, Bizai ML et al. Humoral Immune Response against P2{beta} from Trypanosoma cruzi in Persons with Chronic Chagas Disease: Its Relationship with Treatment Against Parasites and Myocardial Damage. Am. J. Trop. Med. Hyg. 84(4), 575–580 (2011).
   PubMed Web of Science ®Google Scholar
• Vercosa AF, Lorena VM, Carvalho CL et al. Chagas’ disease: IgG isotypes against cytoplasmic (CRA) and flagellar (FRA) recombinant repetitive antigens of Trypanosoma cruzi in chronic Chagasic patients. J. Clin. Lab. Anal. 21(5), 271–276 (2007).
   PubMedGoogle Scholar
• Vasconcelos RH, Amaral FN, Cavalcanti MG et al. Increased levels of IgA antibodies against CRA and FRA recombinant antigens of Trypanosoma cruzi differentiate digestive forms of Chagas disease. Hum. Immunol. 71(10), 964–967 (2010).
   PubMedGoogle Scholar
• Rocha A, de Oliveira LC, Alves RS, Lopes ER. [Pancreatic neuronal loss in chronic Chagas’ disease patients]. Rev. Soc. Bras. Med. Trop. 31(1), 43–49 (1998).
   PubMedGoogle Scholar
• dos Santos VM, de Lima MA, Cabrine-Santos M et al. Functional and histopathological study of the pancreas in hamsters (Mesocricetus auratus) infected and reinfected with Trypanosoma cruzi. Parasitol. Res. 94(2), 125–133 (2004).
   PubMedGoogle Scholar
• Oliveira LC, Juliano Y, Novo NF, Neves MM. Blood glucose and insulin response to intravenous glucose by patients with chronic Chagas’ disease and alcoholism. Braz. J. Med. Biol. Res. 26(11), 1187–1190 (1993).
   PubMedGoogle Scholar
• Guariento ME, Saad MJ, Muscelli EO, Gontijo JA. Heterogenous insulin response to an oral glucose load by patients with the indeterminate clinical form of Chagas’ disease. Braz. J. Med. Biol. Res. 26(5), 491–495 (1993).
   PubMedGoogle Scholar
• dos Santos VM, da Cunha SF, Teixeira Vde P et al. [Frequency of diabetes mellitus and hyperglycemia in chagasic and non-chagasic women]. Rev. Soc. Bras. Med. Trop. 32(5), 489–496 (1999).
   PubMedGoogle Scholar
• Combs TP, Nagajyothi, Mukherjee S et al. The adipocyte as an important target cell for Trypanosoma cruzi infection. J. Biol. Chem. 280(25), 24085–24094 (2005).
   PubMed Web of Science ®Google Scholar
• Nagajyothi F, Desruisseaux MS, Thiruvur N et al. Trypanosoma cruzi infection of cultured adipocytes results in an inflammatory phenotype. Obesity (Silver Spring), 16(9), 1992–1997 (2008).
   PubMedGoogle Scholar
• Schulze PC, Kratzsch J. Leptin as a new diagnostic tool in chronic heart failure. Clin. Chim. Acta. 362(1–2), 1–11 (2005).
   PubMed Web of Science ®Google Scholar
• Richartz BM, Lotze U, Krack A, Gastmann A, Kuthe F, Figulla HR. [Leptin: a parameter for metabolic changes in heart failure]. Z. Kardiol. 90(4), 280–285 (2001).
   PubMedGoogle Scholar
• Fernandes F, Dantas S, Ianni BM et al. Leptin levels in different forms of Chagas’ disease. Braz. J. Med. Biol. Res. 40(12), 1631–1636 (2007).
   PubMed Web of Science ®Google Scholar
• Ndao M, Spithill TW, Caffrey R et al. Identification of novel diagnostic serum biomarkers for Chagas’ disease in asymptomatic subjects by mass spectrometric profiling. J. Clin. Microbiol. 48(4), 1139–1149 (2010).
   PubMed Web of Science ®Google Scholar
• Cano RC, Rubiolo ER, Santamarina NO. Levels of apolipoproteins and cholesterol of low and high density lipoproteins in asymptomatic Chagas disease. Medicina (B Aires), 45(3), 269–272 (1985).
   PubMedGoogle Scholar
• Rivera MT, de Souza AP, Moreno AH et al. Progressive Chagas’ cardiomyopathy is associated with low selenium levels. Am. J. Trop. Med. Hyg. 66(6), 706–712 (2002).
   PubMed Web of Science ®Google Scholar
• Jelicks LA, de Souza AP, Araujo-Jorge TC, Tanowitz HB. Would selenium supplementation aid in therapy for Chagas disease? Trends Parasitol. 27(3), 102–105 (2011).
   Google Scholar
• Neve J. Selenium as a risk factor for cardiovascular diseases. J. Cardiovasc. Risk 3(1), 42–47 (1996).
   PubMedGoogle Scholar
• Xu GL, Wang SC, Gu BQ et al. Further investigation on the role of selenium deficiency in the aetiology and pathogenesis of Keshan disease. Biomed. Environ. Sci. 10(2–3), 316–326 (1997).
   PubMedGoogle Scholar
• Vanderpas JB, Contempre B, Duale NL et al. Iodine and selenium deficiency associated with cretinism in northern Zaire. Am. J. Clin. Nutr. 52(6), 1087–1093 (1990).
   PubMedGoogle Scholar
• Gomez RM, Solana ME, Levander OA. Host selenium deficiency increases the severity of chronic inflammatory myopathy in Trypanosoma cruzi-inoculated mice. J. Parasitol. 88(3), 541–547 (2002).
   PubMed Web of Science ®Google Scholar
• Souza AP, Jelicks LA, Tanowitz HB et al. The benefits of using selenium in the treatment of Chagas disease: prevention of right ventricle chamber dilatation and reversion of Trypanosoma cruzi-induced acute and chronic cardiomyopathy in mice. Mem. Inst. Oswaldo Cruz 105(6), 746–751 (2010).
   PubMed Web of Science ®Google Scholar
• de Souza AP, de Oliveira GM, Vanderpas J, de Castro SL, Rivera MT, Araujo-Jorge TC. Selenium supplementation at low doses contributes to the decrease in heart damage in experimental Trypanosoma cruzi infection. Parasitol. Res. 91(1), 51–54 (2003).
   PubMed Web of Science ®Google Scholar
• de Souza AP, Sieberg R, Li H et al. The role of selenium in intestinal motility and morphology in a murine model of Typanosoma cruzi infection. Parasitol. Res. 106(6), 1293–1298 (2010).
   PubMed Web of Science ®Google Scholar
• Davis CD, Brooks L, Calisi C, Bennett BJ, McElroy DM. Beneficial effect of selenium supplementation during murine infection with Trypanosoma cruzi. J. Parasitol. 84(6), 1274–1277 (1998).
   PubMed Web of Science ®Google Scholar
• Fernandes F, Barbosa-Ferreira JM, Mady C. New diagnostic serum biomarkers for Chagas disease. Expert Opin. Med. Diagn. 5(3), 203–211 (2011).
   Google Scholar
• Salomone OA. Chagas’ cardiomyopathy and thrombosis: the beginning and the end of a dangerous affair. Rev. Esp. Cardiol. 56(4), 333–334 (2003).
   PubMedGoogle Scholar
• Carod-Artal FJ, Gascon J. Chagas disease and stroke. Lancet Neurol. 9(5), 533–542 (2010).
   PubMed Web of Science ®Google Scholar
• Paixao LC, Ribeiro AL, Valacio RA, Teixeira AL. Chagas disease: independent risk factor for stroke. Stroke 40(12), 3691–3694 (2009).
   PubMed Web of Science ®Google Scholar
• Carod-Artal FJ, Vargas AP, Horan TA, Nunes LG. Chagasic cardiomyopathy is independently associated with ischemic stroke in Chagas disease. Stroke 36(5), 965–970 (2005).
   PubMed Web of Science ®Google Scholar
• Carod-Artal FJ. [Chagas’ disease and ischemic stroke]. Neurologia 21(3), 135–149 (2006).
   PubMedGoogle Scholar
• Carod-Artal FJ. Chagas cardiomyopathy and ischemic stroke. Expert Rev. Cardiovasc. Ther. 4(1), 119–130 (2006).
   PubMedGoogle Scholar
• Carod-Artal FJ. Stroke: a neglected complication of American trypanosomiasis (Chagas’ disease). Trans. R. Soc. Trop. Med. Hyg. 101(11), 1075–1080 (2007).
   PubMed Web of Science ®Google Scholar
• Mohallem SV, Ramos SG, dos Reis MA, Seabra DD, Teixeira Vde P. [Prevalence of renal infarcts in autopsies of chronic Chagas disease patients]. Rev. Soc. Bras. Med. Trop. 29(6), 571–574 (1996).
   PubMedGoogle Scholar
• Reverter. Prothrombotic markers in Chagas disease. Enfermedades Emergentes 11(Suppl. 1), 42–47 (2009).
   Google Scholar
• Carod-Artal FJ, Vargas AP, Falcao T. Stroke in asymptomatic Trypanosoma cruzi-infected patients. Cerebrovasc. Dis. 31(1), 24–28 (2011).
   PubMedGoogle Scholar
• Berra HH, Piaggio E, Revelli SS, Luquita A. Blood viscosity changes in experimentally Trypanosoma cruzi-infected rats. Clin. Hemorheol. Microcirc. 32(3), 175–182 (2005).
   PubMedGoogle Scholar
• Tanowitz HB, Burns ER, Sinha AK et al. Enhanced platelet adherence and aggregation in Chagas’ disease: a potential pathogenic mechanism for cardiomyopathy. Am. J. Trop. Med. Hyg. 43(3), 274–281 (1990).
   PubMed Web of Science ®Google Scholar
• Herrera RN, Diaz E, Perez R et al. [The prothrombotic state in early stages of chronic chagas’ disease]. Rev. Esp. Cardiol. 56(4), 377–382 (2003).
   PubMedGoogle Scholar
• de Melo LM, Souza GE, Valim LR et al. Study of pro-thrombotic and pro-inflammatory factors in Chagas cardiomyopathy. Arq. Bras. Cardiol. 95(5), 655–662 (2010).
   PubMedGoogle Scholar
• Herrera RN, Amaya EI, Perez Aguilar RC et al. Inflammatory and Prothrombotic Activation With Conserved Endothelial Function in Patients With Chronic, Asymptomatic Chagas Disease. Clin. Appl. Thromb. Hemost. 17(5), 502–507 (2011).
   PubMedGoogle Scholar
• Herrera RN, Diaz E, Perez Aguilar R, Bianchi J, Berman S, Luciardi HL. [Prothrombotic state in early stages of chronic Chagas’ disease. Its association with thrombotic risk factors]. Arch. Cardiol. Mex. 75 (Suppl. 3), S3–38–48 (2005).
   Google Scholar
• Pinazo MJ, Tassies D, Munoz J et al. Hypercoagulability biomarkers in Trypanosoma cruzi-infected patients. Thromb. Haemost. 106(4), 617–623 (2011).
   PubMed Web of Science ®Google Scholar
• George FD. Microparticles in vascular diseases. Thromb. Res. 122(Suppl. 1), S55–59 (2008).
   PubMedGoogle Scholar
• Enjeti AK, Lincz LF, Seldon M. Detection and measurement of microparticles: an evolving research tool for vascular biology. Semin. Thromb. Hemost. 33(8), 771–779 (2007).
   PubMedGoogle Scholar
• Ashton AW, Mukherjee S, Nagajyothi FN et al. Thromboxane A2 is a key regulator of pathogenesis during Trypanosoma cruzi infection. J. Exp. Med. 204(4), 929–940 (2007).
   PubMedGoogle Scholar
• Laucella SA, Segura EL, Riarte A, Sosa ES. Soluble platelet selectin (sP-selectin) and soluble vascular cell adhesion molecule-1 (sVCAM-1) decrease during therapy with benznidazole in children with indeterminate form of Chagas’ disease. Clin. Exp. Immunol. 118(3), 423–427 (1999).
   PubMed Web of Science ®Google Scholar
• Forastiero RR, Martinuzzo ME, Broze GJ. High titers of autoantibodies to tissue factor pathway inhibitor are associated with the antiphospholipid syndrome. J. Thromb. Haemost. 1(4), 718–724 (2003).
   PubMedGoogle Scholar
• Brasil PE, De Castro L, Hasslocher-Moreno AM, Sangenis LH, Braga JU. ELISA versus PCR for diagnosis of chronic Chagas disease: systematic review and meta-analysis. BMC Infect. Dis. 10, 337 (2010).
   PubMedGoogle Scholar
• Schijman AG, Bisio M, Orellana L et al. International study to evaluate PCR methods for detection of Trypanosoma cruzi DNA in blood samples from Chagas disease patients. PLoS Negl. Trop. Dis. 5(1), e931 (2011).
   PubMed Web of Science ®Google Scholar
• Britto CC. Usefulness of PCR-based assays to assess drug efficacy in Chagas disease chemotherapy: value and limitations. Mem. Inst. Oswaldo Cruz 104(Suppl. 1), 122–135 (2009).
   PubMedGoogle Scholar